• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Nutrients >A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine
【2h】

A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine

机译：一项关于慢性炎性疾病的治疗选择和生活方式建议的研究的提案：丹麦预后因素和个性化医学的多学科合作

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.
机译：用靶向促炎性分子的生物制剂治疗包括克罗恩氏病和溃疡性结肠炎（炎症性肠病，IBD），类风湿性关节炎，牛皮癣，银屑病关节炎，脊柱关节炎，慢性化脓性汗腺炎和免疫介导的葡萄膜炎在内的慢性炎症性疾病（CID）。肿瘤坏死因子-α（TNF）（即TNF抑制剂）。大约三分之一的患者对治疗无反应。遗传和生活方式可能会影响治疗效果。这种多学科合作的目的是确定（1）具有预后价值的分子标志，以帮助根据可能要启动TNF抑制剂治疗的个体制定治疗决策，其次是（2）支持实现最佳治疗结果的生活方式因素。本报告描述了旨在获取此信息的同类人群的建立。在进行TNF抑制剂治疗之前和期间，应收集临床数据，包括生活方式和治疗反应以及生物学标本（血液，粪便，尿液以及IBD患者的肠道活检）。假设驱动分析和数据驱动分析都将根据预先指定的方案进行，包括从候选基因表达分析和整体方法（例如代谢组学，宏基因组学，蛋白质组学）产生的途径分析。最终目的是通过提供有助于治疗选择和可能改善临床结局的饮食建议的工具，改善患有CID的患者的生活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号